Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
The Impact of Initiating/Switching to Insulin Detemir on Emotional Well-being and Treatment Satisfaction
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 299
- Registration Number
- NCT01542476
Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 Diabetes
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4464
- Registration Number
- NCT01542463
Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos
Completed
- Conditions
- Diabetes Mellitus, Type 2DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 480
- Registration Number
- NCT01542489
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia
Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus
- First Posted Date
- 2012-03-01
- Last Posted Date
- 2012-04-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 298
- Registration Number
- NCT01542060
Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-02-29
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 135
- Registration Number
- NCT01541215
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Southampton, United Kingdom
Special Survey for Patients With Type 1 or Type 2 Diabetes
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2012-02-24
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1582
- Registration Number
- NCT01538589
Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Drug: biphasic insulin aspart 70
- First Posted Date
- 2012-02-24
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 59
- Registration Number
- NCT01538511
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Paediatric Subjects - Special Survey
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-02-24
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 71
- Registration Number
- NCT01538576
Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 Diabetes
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4994
- Registration Number
- NCT01536652
Post Marketing Surveillance Study of Biphasic Insulin Aspart 30
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 5346
- Registration Number
- NCT01536613
© Copyright 2025. All Rights Reserved by MedPath